Literature DB >> 8380463

Role of N-linked glycans in antigenicity, processing, and cell surface expression of bovine herpesvirus 1 glycoprotein gIV.

S K Tikoo1, M D Parker, J V van den Hurk, J Kowalski, T J Zamb, L A Babiuk.   

Abstract

Glycoprotein gIV, a structural component of bovine herpesvirus type 1, stimulates high titers of virus-neutralizing antibody. The protein contains three potential sites for the addition of N-linked carbohydrates. Three mutants were constructed by oligonucleotide-directed mutagenesis, in each case changing one N-linked glycosylation site from Asn-X-Thr/Ser to Ser-X-Thr/Ser. A fourth mutant was altered at two sites. The altered forms of the gIV gene were cloned into a vaccinia virus transfer vector to generate recombinant vaccinia viruses expressing mutant proteins. Analysis of these mutants revealed that only two (residues 41 and 102) of the three (residues 41, 102, and 411) potential sites for the addition of N-linked glycans are actually utilized. Absence of glycans at residue 41 (gN1) showed no significant effect on the conformation of the protein or induction of a serum neutralizing antibody response. However, mutant proteins lacking glycans at residue 102 (gN2) or residues 41 and 102 (gN1N2) showed altered reactivity with conformation-dependent gIV-specific monoclonal antibodies. These mutants also induced significantly lower serum neutralizing antibody responses than wild-type gIV. Nonetheless, each of the mutant proteins were modified by the addition of O-glycans and transported to the cell surface. Our results demonstrate that absence of N-linked glycans at one (residue 102) or both (residues 41 and 102) utilized N-linked glycosylation sites alters the conformation but does not prevent processing and transport of gIV to the cell surface.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380463      PMCID: PMC237424     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Synthesis and processing of bovine herpesvirus 1 glycoproteins.

Authors:  S van Drunen Littel-van den Hurk; L A Babiuk
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

2.  Amino acid sequences in the alpha 1 domain and not glycosylation are important in HLA-A2/beta 2-microglobulin association and cell surface expression.

Authors:  J Santos-Aguado; P A Biro; U Fuhrmann; J L Strominger; J A Barbosa
Journal:  Mol Cell Biol       Date:  1987-03       Impact factor: 4.272

3.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

Review 4.  Carbohydrate moieties of glycoproteins. A re-evaluation of their function.

Authors:  K Olden; J B Parent; S L White
Journal:  Biochim Biophys Acta       Date:  1982-05-12

5.  Protection of cattle from bovine herpesvirus type I (BHV-1) infection by immunization with individual viral glycoproteins.

Authors:  L A Babiuk; J L'Italien; S van Drunen Littel-van den Hurk; T Zamb; J P Lawman; G Hughes; G A Gifford
Journal:  Virology       Date:  1987-07       Impact factor: 3.616

6.  A single N-linked oligosaccharide at either of the two normal sites is sufficient for transport of vesicular stomatitis virus G protein to the cell surface.

Authors:  C E Machamer; R Z Florkiewicz; J K Rose
Journal:  Mol Cell Biol       Date:  1985-11       Impact factor: 4.272

7.  Expression of bovine herpesvirus 1 glycoproteins gI and gIII in transfected murine cells.

Authors:  D R Fitzpatrick; T Zamb; M D Parker; S van Drunen Littel-van den Hurk; L A Babiuk; M J Lawman
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Functional and topographical analyses of epitopes on bovine herpesvirus type 1 glycoprotein IV.

Authors:  G Hughes; L A Babiuk; S van Drunen Littel-van den Hurk
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

10.  Effect of tunicamycin and monensin on biosynthesis, transport, and maturation of bovine herpesvirus type-1 glycoproteins.

Authors:  S van Drunen Littel-van den Hurk; L A Babiuk
Journal:  Virology       Date:  1985-05       Impact factor: 3.616

View more
  6 in total

1.  Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response.

Authors:  P J Lewis; L A Babiuk
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

2.  Glycoprotein D of bovine herpesvirus 5 (BoHV-5) confers an extended host range to BoHV-1 but does not contribute to invasion of the brain.

Authors:  Evgeni Gabev; Kurt Tobler; Carlos Abril; Monika Hilbe; Claudia Senn; Marco Franchini; Gabriella Campadelli-Fiume; Cornel Fraefel; Mathias Ackermann
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

3.  Bovine herpesvirus 1 UL49.5 homolog gene encodes a novel viral envelope protein that forms a disulfide-linked complex with a second virion structural protein.

Authors:  X Liang; B Chow; C Raggo; L A Babiuk
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

4.  Loss of N-linked glycosylation from the hemagglutinin-neuraminidase protein alters virulence of Newcastle disease virus.

Authors:  Aruna Panda; Subbiah Elankumaran; Sateesh Krishnamurthy; Zhuhui Huang; Siba K Samal
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Analysis of bovine herpesvirus 1 glycoprotein gIV truncations and deletions expressed by recombinant vaccinia viruses.

Authors:  S K Tikoo; T J Zamb; L A Babiuk
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

6.  Cellular targeting of engineered heterologous antigens is a determinant factor for bovine herpesvirus 4-based vaccine vector development.

Authors:  Gaetano Donofrio; Valentina Franceschi; Antonio Capocefalo; Simone Taddei; Chiara Sartori; Sabrina Bonomini; Sandro Cavirani; Clotilde S Cabassi; Cesidio F Flammini
Journal:  Clin Vaccine Immunol       Date:  2009-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.